{"filings":[{"id":107906,"accession_number":"0001477932-26-001379","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics","event_type":"leadership","confidence":"high","bullets":["Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.","He brings 15+ years experience in oncology diagnostics, previously at Menarini, Congenica, Variantyx, and QIAGEN.","BioNexus holds exclusive commercialization rights for VitaGuard in Southeast Asia through its Fidelion investment.","MRD testing is a fast-growing precision oncology segment for early cancer recurrence detection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107905,"accession_number":"0001477932-26-000964","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab Corp. completes Chemrex governance restructuring; appoints Matthew Barsing as Chairman","event_type":"other_material","confidence":"high","bullets":["Chemrex board streamlined to two directors: Matthew L. Barsing (Chairman) and Angeline Chong (Director, BioNexus CFO).","New officers expected in coming months; Chemrex remains wholly owned subsidiary under parent oversight.","July 2025 capital allocation framework approved for potential operational upgrades, subject to evaluation.","No definitive commitments on scope, timing, or scale of any initiative under evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107904,"accession_number":"0001477932-26-000610","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests","event_type":"other_material","confidence":"high","bullets":["Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.","Annual cancer incidence in region projected at 2.4M cases by 2030; company sees multi-billion-dollar market shift.","Fidelion Diagnostics Pte. Ltd. established as exclusive IP and commercialization vehicle outside Greater China.","Foundational steps completed by end 2025: global patent filings, recruitment, and regulatory prep with regional diagnostics partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124322,"accession_number":"0001477932-25-009240","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioNexus Gene Lab Corp. shareholders elect all four director nominees and approve 2025 equity plan","event_type":"other","confidence":"high","bullets":["Directors re-elected: Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, Chee Keong Yap.","2025 Equity Incentive Plan approved with 966,759.8 votes for, 10,628.5 against.","JP Centurion & Partners PLT ratified as independent auditor for FY 2025.","Adjournment proposal approved if needed to solicit additional proxies.","All proposals passed; meeting held December 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124321,"accession_number":"0001477932-25-009186","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Chemrex subsidiary governance shake-up: four directors resign; new chairman appointed","event_type":"other_material","confidence":"high","bullets":["Four Chemrex officers/directors (Too Kam Tham, Liong Tai Tan, Wei Foong Lim, Kuan Yew Tan) resigned on Dec 19, 2025.","Matthew L. Barsing appointed as chairman of Chemrex board; brings tech and public-sector experience.","Chemrex governance review ongoing, assessing historical compliance, governance, and operational matters.","Chemrex exploring potential CDMO expansion as part of strategic shift toward biotech development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124320,"accession_number":"0001477932-25-008724","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab secures $500M equity facility from ARC and exclusive VitaGuard MRD license in SE Asia","event_type":"other_material","confidence":"high","bullets":["ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.","BGLC obtains exclusive, perpetual, royalty-free license for VitaGuard MRD liquid biopsy platform in Southeast Asia; $2M fee over 24 months, $500K minimum reagent purchases.","As part of strategic alliance, BGLC issued 392,329 shares to Fidelion (now 16.6% owner) and received 180 Fidelion shares (15% stake).","$500M facility complements $20M ATM program; BGLC retains discretion on draws. ARC prohibited from short-selling or hedging."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124319,"accession_number":"0001477932-25-008137","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioNexus files $100M shelf, enters $20M ATM with Maxim Group","event_type":"other_material","confidence":"high","bullets":["Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.","Filed S-3 shelf registration registering up to $100M of securities, not yet effective.","Proceeds to support growth initiatives: term sheets with Fidelion Diagnostics (VitaGuard MRD) and BirchBioMed Inc.","Company focuses on precision diagnostics, gene-based technologies in Asia and U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124318,"accession_number":"0001477932-25-008044","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia","event_type":"m_and_a","confidence":"high","bullets":["BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.","CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.","VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.","Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.","Conditions include IP license agreement; other definitive agreements not yet executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124317,"accession_number":"0001477932-25-007708","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia","event_type":"other_material","confidence":"high","bullets":["BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.","BGLC will receive 1.5 million common shares of BirchBioMed in exchange.","Collaboration to commercialize FS2 (kynurenic acid) topical cream in Malaysia and Singapore.","Term sheet non-binding except 60-day exclusivity; no assurance definitive agreement will be reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140992,"accession_number":"0001477932-25-005322","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia","event_type":"m_and_a","confidence":"high","bullets":["BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.","VitaGuard is tumour-naïve ctDNA test with 0.02% VAF sensitivity, 95% cfDNA recovery; cost <$300 vs >$3,000 legacy assays.","Southeast Asia cancer incidence projected at 2.4M new cases annually by 2030, creating multi-billion-dollar recurring market.","Cross-shareholdings and license fee align both companies; rollout begins in Singapore and Malaysia.","Partnership includes joint development of companion diagnostics and AI-powered Cancer Interception System."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158764,"accession_number":"0001477932-25-004754","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioNexus Gene Lab appoints Chong Set Fui as CFO effective immediately","event_type":"leadership","confidence":"high","bullets":["Appointed Chong Set Fui (Angeline) as CFO and Principal Financial Officer, effective June 17, 2025.","Chong has 25+ years senior financial experience, most recently CFO of Avillion Berhad (2013-2024).","Monthly salary RM15,000 (~$3,500 USD) plus medical, fuel allowance, and discretionary bonus.","Appointment is for a fixed term from June 17, 2025 to June 16, 2027, renewable with one-month notice.","Su-Leng Tan Lee ceased as acting CFO concurrently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}